Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease
Many physicians retain reservations regarding the routine prescription of renin-angiotensin blockade (RAB) in patients with atheromatous renovascular disease (ARVD). Conversely, these patients are in most need of the cardio- and renal protection offered by RAB. This reservation is mostly because of...
Saved in:
Published in | Nephrology, dialysis, transplantation Vol. 27; no. 4; pp. 1403 - 1409 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Oxford University Press
01.04.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Many physicians retain reservations regarding the routine prescription of renin-angiotensin blockade (RAB) in patients with atheromatous renovascular disease (ARVD). Conversely, these patients are in most need of the cardio- and renal protection offered by RAB. This reservation is mostly because of fear of precipitating acute renal deterioration. We aimed to study whether RAB can be used safely in ARVD patients and whether it altered their outcome.
Prospective observational study of all ARVD patients presenting to our tertiary referral centre from 1999-2009. Data capture included usage and tolerability of RAB, and correlation with endpoints of cardiovascular events, dialysis or death.
Six hundred and twenty-one subjects were available for analysis. Mean age (SD) of the cohort was 71.3 (8.8) years, median (interquartile range) follow-up 3.1 (2.1, 4.8), range 0.2-10.61 years. Seventy-four patients had an intolerance to RAB at study entry. When utilized prospectively, RAB was tolerated in 357 of 378 patients (92%), and this was even seen in 54/69 (78.3%) patients with bilateral>60% renal artery stenosis (RAS) or occlusion. Patients (4/21) who were intolerant of RAB during follow-up (and 12 retrospectively intolerant), underwent renal revascularization which facilitated safe use of these medications post-procedure. On multivariate time-adjusted analysis, patients receiving RAB were significantly less likely to die (P=0.02).
RAB is well tolerated even in patients with bilateral severe RAS and reduced mortality in a large group of ARVD patients. We recommend all ARVD patients be considered for RAB therapy unless an absolute contra-indication exists. Intolerance of these agents due to renal dysfunction should be considered an emerging indication for renal revascularization to facilitate their re-introduction. |
---|---|
AbstractList | Many physicians retain reservations regarding the routine prescription of renin-angiotensin blockade (RAB) in patients with atheromatous renovascular disease (ARVD). Conversely, these patients are in most need of the cardio- and renal protection offered by RAB. This reservation is mostly because of fear of precipitating acute renal deterioration. We aimed to study whether RAB can be used safely in ARVD patients and whether it altered their outcome.
Prospective observational study of all ARVD patients presenting to our tertiary referral centre from 1999-2009. Data capture included usage and tolerability of RAB, and correlation with endpoints of cardiovascular events, dialysis or death.
Six hundred and twenty-one subjects were available for analysis. Mean age (SD) of the cohort was 71.3 (8.8) years, median (interquartile range) follow-up 3.1 (2.1, 4.8), range 0.2-10.61 years. Seventy-four patients had an intolerance to RAB at study entry. When utilized prospectively, RAB was tolerated in 357 of 378 patients (92%), and this was even seen in 54/69 (78.3%) patients with bilateral>60% renal artery stenosis (RAS) or occlusion. Patients (4/21) who were intolerant of RAB during follow-up (and 12 retrospectively intolerant), underwent renal revascularization which facilitated safe use of these medications post-procedure. On multivariate time-adjusted analysis, patients receiving RAB were significantly less likely to die (P=0.02).
RAB is well tolerated even in patients with bilateral severe RAS and reduced mortality in a large group of ARVD patients. We recommend all ARVD patients be considered for RAB therapy unless an absolute contra-indication exists. Intolerance of these agents due to renal dysfunction should be considered an emerging indication for renal revascularization to facilitate their re-introduction. BACKGROUNDMany physicians retain reservations regarding the routine prescription of renin-angiotensin blockade (RAB) in patients with atheromatous renovascular disease (ARVD). Conversely, these patients are in most need of the cardio- and renal protection offered by RAB. This reservation is mostly because of fear of precipitating acute renal deterioration. We aimed to study whether RAB can be used safely in ARVD patients and whether it altered their outcome.METHODSProspective observational study of all ARVD patients presenting to our tertiary referral centre from 1999-2009. Data capture included usage and tolerability of RAB, and correlation with endpoints of cardiovascular events, dialysis or death.RESULTSSix hundred and twenty-one subjects were available for analysis. Mean age (SD) of the cohort was 71.3 (8.8) years, median (interquartile range) follow-up 3.1 (2.1, 4.8), range 0.2-10.61 years. Seventy-four patients had an intolerance to RAB at study entry. When utilized prospectively, RAB was tolerated in 357 of 378 patients (92%), and this was even seen in 54/69 (78.3%) patients with bilateral>60% renal artery stenosis (RAS) or occlusion. Patients (4/21) who were intolerant of RAB during follow-up (and 12 retrospectively intolerant), underwent renal revascularization which facilitated safe use of these medications post-procedure. On multivariate time-adjusted analysis, patients receiving RAB were significantly less likely to die (P=0.02).CONCLUSIONRAB is well tolerated even in patients with bilateral severe RAS and reduced mortality in a large group of ARVD patients. We recommend all ARVD patients be considered for RAB therapy unless an absolute contra-indication exists. Intolerance of these agents due to renal dysfunction should be considered an emerging indication for renal revascularization to facilitate their re-introduction. |
Author | FOLEY, Robert N YOUNG, James F CHRYSOCHOU, Constantina KHAVANDI, Kaivan CHEUNG, Ching M KALRA, Philip A |
Author_xml | – sequence: 1 givenname: Constantina surname: CHRYSOCHOU fullname: CHRYSOCHOU, Constantina organization: Renal department, Salford Royal Hospital, Manchester Academic Health Science Centre, The University of Manchester, Salford, United Kingdom – sequence: 2 givenname: Robert N surname: FOLEY fullname: FOLEY, Robert N organization: Chronic Disease Research Group, School of Medicine, University of Minnesota—Twin Cities, Minneapolis, MN, United States – sequence: 3 givenname: James F surname: YOUNG fullname: YOUNG, James F organization: Renal department, Salford Royal Hospital, Manchester Academic Health Science Centre, The University of Manchester, Salford, United Kingdom – sequence: 4 givenname: Kaivan surname: KHAVANDI fullname: KHAVANDI, Kaivan organization: Renal department, Salford Royal Hospital, Manchester Academic Health Science Centre, The University of Manchester, Salford, United Kingdom – sequence: 5 givenname: Ching M surname: CHEUNG fullname: CHEUNG, Ching M organization: Renal department, Salford Royal Hospital, Manchester Academic Health Science Centre, The University of Manchester, Salford, United Kingdom – sequence: 6 givenname: Philip A surname: KALRA fullname: KALRA, Philip A organization: Renal department, Salford Royal Hospital, Manchester Academic Health Science Centre, The University of Manchester, Salford, United Kingdom |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25703139$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21993376$$D View this record in MEDLINE/PubMed |
BookMark | eNpF0EtLxDAQB_Agiq6Pix9AehFBqObRbhJv4hsEL3ous-lkjbbJmrTCfnuju-ppBubHMPPfJZs-eCTkkNEzRrU49-1wPrex0tMNMmHVlJZcqHqTTPKQlbSmeofspvRGKdVcym2yw5nWQsjphDTXLi2w65yfF8MrFv1yeL346caERbBFRO98CX7uwoA-OV_MumDeocUi95BlDD0MYUzfNHxCMmMHsWhdQki4T7YsdAkP1nWPvNzePF_dl49Pdw9Xl4-lqZgaSmWxMoJK2YIUxs6MsVXNjZIcal7RuhZWtDMjmEEjLYCVtOYaONVWSdSt2CMnq72LGD5GTEPTu2TyY-Ax39boqVBcK6WyPF1JE0NKEW2ziK6HuGwYbb7zbHKezSrPjI_Wa8dZj-0f_Q0wg-M1yI9DZyN449K_qyUVTGjxBUqpgpE |
CODEN | NDTREA |
CitedBy_id | crossref_primary_10_1093_ajh_hpaa016 crossref_primary_10_2215_CJN_04240414 crossref_primary_10_2215_CJN_09030813 crossref_primary_10_1097_HCO_0000000000000790 crossref_primary_10_1016_j_med_2023_06_020 crossref_primary_10_1016_j_coph_2018_01_009 crossref_primary_10_2174_1573402115666190416153321 crossref_primary_10_1016_j_mpmed_2015_04_008 crossref_primary_10_1097_MNH_0000000000000202 crossref_primary_10_1093_ajh_hpx154 crossref_primary_10_1016_j_mcna_2016_08_010 crossref_primary_10_1093_ndt_gfad095 crossref_primary_10_1007_s11560_023_00692_0 crossref_primary_10_1681_ASN_2014121274 crossref_primary_10_5758_vsi_2017_33_1_1 crossref_primary_10_1093_ndt_gft073 crossref_primary_10_1007_s11883_014_0416_2 crossref_primary_10_1016_j_cpcardiol_2017_01_004 crossref_primary_10_1097_MOP_0000000000001209 crossref_primary_10_1097_HJH_0000000000000324 crossref_primary_10_1016_j_ccl_2014_09_006 crossref_primary_10_1038_nrneph_2011_164 crossref_primary_10_38109_2225_1685_2023_1_6_65 crossref_primary_10_1097_MJT_0000000000000224 crossref_primary_10_1093_ndt_gfw107 crossref_primary_10_1016_j_jash_2015_03_007 crossref_primary_10_32895_UMP_MPR_6_3_S3 crossref_primary_10_1097_MNH_0000000000000513 crossref_primary_10_1038_s41440_019_0284_9 crossref_primary_10_1177_2324709618816501 crossref_primary_10_1093_ndt_gfy157 crossref_primary_10_1053_j_semnuclmed_2013_10_006 crossref_primary_10_1053_j_ackd_2014_10_004 crossref_primary_10_1097_MNH_0b013e328363ffe0 crossref_primary_10_1186_s12882_016_0409_1 crossref_primary_10_1186_s40885_020_00140_4 crossref_primary_10_1161_HYPERTENSIONAHA_123_21362 crossref_primary_10_1159_000447753 crossref_primary_10_1136_bcr_2021_242724 crossref_primary_10_1161_HYP_0000000000000084 crossref_primary_10_1016_j_kint_2021_04_029 crossref_primary_10_1016_j_jdmv_2018_02_006 crossref_primary_10_1038_ki_2013_144 crossref_primary_10_3390_jcm13051471 crossref_primary_10_1053_j_ajkd_2021_06_025 crossref_primary_10_1016_j_lpmfor_2024_01_004 crossref_primary_10_2215_CJN_11611113 crossref_primary_10_1161_HYPERTENSIONAHA_122_17965 crossref_primary_10_1016_j_jash_2013_01_004 crossref_primary_10_1093_eurheartj_ehx095 crossref_primary_10_1186_s12882_019_1406_y crossref_primary_10_1016_j_ejvs_2017_07_018 crossref_primary_10_1586_14779072_2014_977258 crossref_primary_10_3109_07853890_2012_687834 crossref_primary_10_1007_s11883_014_0459_4 crossref_primary_10_1111_1755_5922_12474 crossref_primary_10_1007_s40256_013_0011_x crossref_primary_10_1016_j_nephro_2016_07_450 crossref_primary_10_3390_jcm13051508 crossref_primary_10_1111_nep_12501 crossref_primary_10_1016_j_carrev_2018_06_008 crossref_primary_10_1097_MNH_0000000000000059 crossref_primary_10_38109_2075_082X_2022_1_49_54 crossref_primary_10_1016_j_amjmed_2015_10_010 crossref_primary_10_1161_HYPERTENSIONAHA_118_11082 crossref_primary_10_1016_j_jash_2015_12_002 crossref_primary_10_3390_diagnostics13142356 crossref_primary_10_1007_s11886_013_0409_8 |
Cites_doi | 10.1681/ASN.2005010043 10.1016/S0140-6736(97)11060-1 10.1093/ndt/15.5.631 10.1161/CIRCULATIONAHA.106.637751 10.1016/j.amjcard.2007.02.098 10.1016/0002-9343(94)90109-0 10.1038/ki.2009.406 10.1111/j.1523-1755.1998.00840.x 10.2215/CJN.07831109 10.1016/0002-9343(85)90075-0 10.1016/S0735-1097(03)00262-6 10.1161/CIRCULATIONAHA.105.592733 10.1056/NEJM200001203420301 10.1159/000078950 10.1016/S0002-9149(97)00060-X 10.1097/HJH.0b013e3282f0580f 10.1093/qjmed/92.9.515 10.1016/S0272-6386(12)80223-X 10.1093/qjmed/hcn039 10.1046/j.1523-1755.1998.00164.x 10.1016/S0272-6386(96)90158-4 10.1097/01.hjh.0000226211.95936.f5 10.7326/0003-4819-134-8-200104170-00007 10.1056/NEJM198302173080706 10.1046/j.1532-5415.2002.50321.x 10.1053/ajkd.2000.17686 10.1111/j.1523-1755.2005.00406.x 10.1097/00045391-200607000-00005 10.1097/01.ASN.0000146423.71226.0C 10.1016/S0140-6736(05)67814-2 10.1093/ndt/gfh865 10.1001/jama.289.19.2560 10.2165/00129784-200202030-00003 10.1038/sj.jhh.1001683 10.1016/S0140-6736(03)14286-9 10.1681/ASN.V2111608 10.7326/0003-4819-135-2-200107170-00007 10.1001/archinte.160.5.685 10.1016/j.jacc.2007.08.029 10.1097/EDE.0b013e3181577654 10.1093/qjmed/89.2.145 10.7326/0003-4819-148-1-200801010-00190 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS |
Copyright_xml | – notice: 2015 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1093/ndt/gfr496 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1460-2385 |
EndPage | 1409 |
ExternalDocumentID | 10_1093_ndt_gfr496 21993376 25703139 |
Genre | Journal Article |
GroupedDBID | --- -E4 .2P .55 .GJ .I3 .XZ .ZR 0R~ 123 18M 1TH 29M 2WC 4.4 482 48X 53G 5RE 5VS 5WA 5WD 6.Y 70D AABJS AABMN AABZA AACZT AAESY AAHTB AAIYJ AAJKP AAJQQ AAMDB AAMVS AANRK AAOGV AAPBV AAPGJ AAPNW AAPQZ AAPXW AAUGY AAUQX AAVAP AAWDT ABEUO ABIXL ABKDP ABNKS ABOCM ABPEJ ABPTD ABPTK ABQLI ABQTQ ABSAR ABSMQ ABWST ABZBJ ACFRR ACGFO ACGFS ACIMA ACPQN ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEIU ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADORX ADQLU ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AFYAG AGINJ AGKEF AGKRT AGQXC AGSYK AGUTN AHMBA AHXPO AIAGR AIJHB AIKOY AIMBJ AJEEA AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APJGH APWMN AQDSO AQKUS ASMCH ASPBG ATTQO AVWKF AWCFO AXUDD AZFZN AZQFJ BAWUL BAYMD BCRHZ BEYMZ BGYMP BHONS BTRTY BVRKM BYORX BZKNY C45 CAG CASEJ CDBKE COF CS3 CZ4 DAKXR DIK DILTD DPORF DPPUQ DU5 D~K E3Z EBS EE~ EIHJH EJD ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX IQODW J21 KAQDR KBUDW KC5 KOP KQ8 KSI KSN M-Z M49 MBLQV MHKGH ML0 N9A NGC NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBFPC OCZFY ODMLO OHH OJQWA OK1 OPAEJ OVD OWPYF O~Y P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RNI ROL ROX ROZ RUSNO RW1 RXO RZF RZO SDH TCURE TEORI TJX TMA TR2 W8F WH7 WOQ X7H X7M YAYTL YKOAZ YXANX ZA5 ZGI ZKX ZXP ~91 AARHZ AAUAY ABJNI ABNHQ ABQNK ABXVV ACMRT ACZBC ADQBN AEHUL AFSHK AGMDO ATGXG AVNTJ CGR CUY CVF ECM EIF HVGLF JXSIZ NPM OJZSN AASNB AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c418t-8fe4c3077da73cfbccf452c872a5240553f3dbc31cec7faaf70529a209f87e9d3 |
ISSN | 0931-0509 |
IngestDate | Fri Aug 16 06:01:02 EDT 2024 Thu Sep 12 22:11:01 EDT 2024 Tue Oct 15 23:40:09 EDT 2024 Sun Oct 22 16:06:21 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Kidney disease cardiovascular events angiotensin-converting enzyme inhibitors Urinary system disease angiotensin receptor blockers Myth Enzyme Hemodialysis atheromatous renovascular disease Peptidases Extrarenal dialysis Renin Angiotensin Renal failure Hydrolases Aspartic endopeptidases Dialysis ACE inhibitor |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c418t-8fe4c3077da73cfbccf452c872a5240553f3dbc31cec7faaf70529a209f87e9d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://academic.oup.com/ndt/article-pdf/27/4/1403/7635541/gfr496.pdf |
PMID | 21993376 |
PQID | 963829888 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_963829888 crossref_primary_10_1093_ndt_gfr496 pubmed_primary_21993376 pascalfrancis_primary_25703139 |
PublicationCentury | 2000 |
PublicationDate | 2012-04-01 |
PublicationDateYYYYMMDD | 2012-04-01 |
PublicationDate_xml | – month: 04 year: 2012 text: 2012-04-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Oxford |
PublicationPlace_xml | – name: Oxford – name: England |
PublicationTitle | Nephrology, dialysis, transplantation |
PublicationTitleAlternate | Nephrol Dial Transplant |
PublicationYear | 2012 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | (43_19275457) 2005; 20 Mailloux (3_15641547) 1994; 24 (42_30718749) 2008; 101 Ihle (4_16277527) 1996; 27 (12_19370412) 2005; 16 Makanjuola (15_6427521) 1999; 92 Burke (20_22270553) 2006; 24 Harding (13_9873759) 1992; 2 Fox (17_17817424) 2003; 362 Bakris (38_6514800) 2000; 160 (41_36551341) 2010; 5 Mann (22_11112932) 2001; 134 (33_29792151) 2008; 148 (10_17637576) 2003; 289 (26_34184545) 1996; 89 Hricik (34_8859688) 1983; 308 Shekelle (39_17624149) 2003; 41 Bart (25_16758285) 1997; 79 The Heart Outcomes Prevention Evaluation Study Inv (16_6426612) 2000; 342 MacDowall (31_6212245) 1998; 352 Williams (9_18048189) 2004; 18 de Silva (14_29051359) 2007; 100 Goldsmith (19_10493140) 2000; 36 van de Ven (37_5967293) 1998; 53 Kalra (1_35888760) 2010; 77 Suresh (28_10314559) 2000; 15 Weinberg (45_18383750) 2004; 24 Ahmed (36_17158534) 2002; 50 Peters (44_6256760) 1998; 54 Casas (5_21237471) 2005; 366 Mancia (11_29340752) 2007; 25 Franklin (21_13634050) 1985; 79 Mann (23_17446777) 2002; 2 Khosla (46_22413046) 2006; 13 (2_23116502) 2007; 115 (18_22323669) 2006; 114 (24_29855483) 2007; 50 Kalra (30_18922339) 2005; 68 von Elm (29_29955790) 2007; 18 Missouris (32_14673860) 1994; 96 Jafar (7_11235714) 2001; 135 Remuzzi (40_18552684) 2004; 15 |
References_xml | – volume: 16 start-page: 2746 issn: 1046-6673 issue: 9 year: 2005 ident: 12_19370412 publication-title: Journal of the American Society of Nephrology doi: 10.1681/ASN.2005010043 – volume: 352 start-page: 13 issn: 0140-6736 issue: 9121 year: 1998 ident: 31_6212245 publication-title: Lancet doi: 10.1016/S0140-6736(97)11060-1 contributor: fullname: MacDowall – volume: 15 start-page: 631 issn: 0931-0509 issue: 5 year: 2000 ident: 28_10314559 publication-title: Nephrology Dialysis Transplantation doi: 10.1093/ndt/15.5.631 contributor: fullname: Suresh – volume: 115 start-page: 50 issn: 0009-7322 issue: 1 year: 2007 ident: 2_23116502 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.637751 – volume: 100 start-page: 273 issn: 0002-9149 issue: 2 year: 2007 ident: 14_29051359 publication-title: The American journal of cardiology doi: 10.1016/j.amjcard.2007.02.098 contributor: fullname: de Silva – volume: 96 start-page: 10 issn: 0002-9343 issue: 1 year: 1994 ident: 32_14673860 publication-title: The American journal of medicine doi: 10.1016/0002-9343(94)90109-0 contributor: fullname: Missouris – volume: 77 start-page: 37 issn: 0085-2538 issue: 1 year: 2010 ident: 1_35888760 publication-title: Kidney international doi: 10.1038/ki.2009.406 contributor: fullname: Kalra – volume: 53 start-page: 986 issn: 0085-2538 issue: 4 year: 1998 ident: 37_5967293 publication-title: Kidney international doi: 10.1111/j.1523-1755.1998.00840.x contributor: fullname: van de Ven – volume: 5 start-page: 623 issn: 1555-9041 issue: 4 year: 2010 ident: 41_36551341 publication-title: Clinical Journal of the American Society of Nephrology doi: 10.2215/CJN.07831109 – volume: 79 start-page: 14 issn: 0002-9343 issue: 3C year: 1985 ident: 21_13634050 publication-title: The American journal of medicine doi: 10.1016/0002-9343(85)90075-0 contributor: fullname: Franklin – volume: 41 start-page: 1529 issn: 0735-1097 issue: 9 year: 2003 ident: 39_17624149 publication-title: Journal of the American College of Cardiology doi: 10.1016/S0735-1097(03)00262-6 contributor: fullname: Shekelle – volume: 114 start-page: 26 issn: 0009-7322 issue: 1 year: 2006 ident: 18_22323669 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.105.592733 – volume: 342 start-page: 145 issn: 0028-4793 issue: 3 year: 2000 ident: 16_6426612 publication-title: New England Journal of Medicine doi: 10.1056/NEJM200001203420301 contributor: fullname: The Heart Outcomes Prevention Evaluation Study Inv – volume: 24 start-page: 340 issn: 0250-8095 issue: 3 year: 2004 ident: 45_18383750 publication-title: American journal of nephrology doi: 10.1159/000078950 contributor: fullname: Weinberg – volume: 79 start-page: 1118 issn: 0002-9149 issue: 8 year: 1997 ident: 25_16758285 publication-title: The American journal of cardiology doi: 10.1016/S0002-9149(97)00060-X contributor: fullname: Bart – volume: 25 start-page: 1751 issn: 0263-6352 issue: 9 year: 2007 ident: 11_29340752 publication-title: Journal of hypertension doi: 10.1097/HJH.0b013e3282f0580f contributor: fullname: Mancia – volume: 92 start-page: 515 issn: 0033-5622 issue: 9 year: 1999 ident: 15_6427521 publication-title: QJM doi: 10.1093/qjmed/92.9.515 contributor: fullname: Makanjuola – volume: 24 start-page: 622 issn: 0272-6386 issue: 4 year: 1994 ident: 3_15641547 publication-title: American journal of kidney diseases : the official journal of the National Kidney Foundation doi: 10.1016/S0272-6386(12)80223-X contributor: fullname: Mailloux – volume: 101 start-page: 519 issn: 0033-5622 issue: 7 year: 2008 ident: 42_30718749 publication-title: QJM doi: 10.1093/qjmed/hcn039 – volume: 54 start-page: 1570 issn: 0085-2538 issue: 5 year: 1998 ident: 44_6256760 publication-title: Kidney international doi: 10.1046/j.1523-1755.1998.00164.x contributor: fullname: Peters – volume: 27 start-page: 489 issn: 0272-6386 issue: 4 year: 1996 ident: 4_16277527 publication-title: American journal of kidney diseases : the official journal of the National Kidney Foundation doi: 10.1016/S0272-6386(96)90158-4 contributor: fullname: Ihle – volume: 24 start-page: 1193 issn: 0263-6352 issue: 6 year: 2006 ident: 20_22270553 publication-title: Journal of hypertension doi: 10.1097/01.hjh.0000226211.95936.f5 contributor: fullname: Burke – volume: 134 start-page: 629 issn: 0003-4819 issue: 8 year: 2001 ident: 22_11112932 publication-title: Annals of Internal Medicine doi: 10.7326/0003-4819-134-8-200104170-00007 contributor: fullname: Mann – volume: 308 start-page: 373 issn: 0028-4793 issue: 7 year: 1983 ident: 34_8859688 publication-title: New England Journal of Medicine doi: 10.1056/NEJM198302173080706 contributor: fullname: Hricik – volume: 50 start-page: 1297 issn: 0002-8614 issue: 7 year: 2002 ident: 36_17158534 publication-title: Journal of the American Geriatrics Society doi: 10.1046/j.1532-5415.2002.50321.x contributor: fullname: Ahmed – volume: 36 start-page: 837 issn: 0272-6386 issue: 4 year: 2000 ident: 19_10493140 publication-title: American journal of kidney diseases : the official journal of the National Kidney Foundation doi: 10.1053/ajkd.2000.17686 contributor: fullname: Goldsmith – volume: 68 start-page: 293 issn: 0085-2538 issue: 1 year: 2005 ident: 30_18922339 publication-title: Kidney international doi: 10.1111/j.1523-1755.2005.00406.x contributor: fullname: Kalra – volume: 13 start-page: 306 issn: 1075-2765 issue: 4 year: 2006 ident: 46_22413046 publication-title: American journal of therapeutics doi: 10.1097/00045391-200607000-00005 contributor: fullname: Khosla – volume: 15 start-page: 3117 issn: 1046-6673 issue: 12 year: 2004 ident: 40_18552684 publication-title: Journal of the American Society of Nephrology doi: 10.1097/01.ASN.0000146423.71226.0C contributor: fullname: Remuzzi – volume: 366 start-page: 2026 issn: 0140-6736 issue: 9502 year: 2005 ident: 5_21237471 publication-title: Lancet doi: 10.1016/S0140-6736(05)67814-2 contributor: fullname: Casas – volume: 20 start-page: 1604 issn: 0931-0509 issue: 8 year: 2005 ident: 43_19275457 publication-title: Nephrology Dialysis Transplantation doi: 10.1093/ndt/gfh865 – volume: 289 start-page: 2560 issn: 0098-7484 issue: 19 year: 2003 ident: 10_17637576 publication-title: JAMA doi: 10.1001/jama.289.19.2560 – volume: 2 start-page: 157 issn: 1175-3277 issue: 3 year: 2002 ident: 23_17446777 publication-title: American journal of cardiovascular drugs : drugs, devices, and other interventions doi: 10.2165/00129784-200202030-00003 contributor: fullname: Mann – volume: 18 start-page: 139 issn: 0950-9240 issue: 3 year: 2004 ident: 9_18048189 publication-title: Journal of human hypertension doi: 10.1038/sj.jhh.1001683 contributor: fullname: Williams – volume: 362 start-page: 782 issn: 0140-6736 issue: 9386 year: 2003 ident: 17_17817424 publication-title: Lancet doi: 10.1016/S0140-6736(03)14286-9 contributor: fullname: Fox – volume: 2 start-page: 1608 issn: 1046-6673 issue: 11 year: 1992 ident: 13_9873759 publication-title: Journal of the American Society of Nephrology doi: 10.1681/ASN.V2111608 contributor: fullname: Harding – volume: 135 start-page: 73 issn: 0003-4819 issue: 2 year: 2001 ident: 7_11235714 publication-title: Annals of Internal Medicine doi: 10.7326/0003-4819-135-2-200107170-00007 contributor: fullname: Jafar – volume: 160 start-page: 685 issn: 0003-9926 issue: 5 year: 2000 ident: 38_6514800 publication-title: Archives of Internal Medicine doi: 10.1001/archinte.160.5.685 contributor: fullname: Bakris – volume: 50 start-page: 2148 issn: 0735-1097 issue: 22 year: 2007 ident: 24_29855483 publication-title: Journal of the American College of Cardiology doi: 10.1016/j.jacc.2007.08.029 – volume: 18 start-page: 800 issn: 1044-3983 issue: 6 year: 2007 ident: 29_29955790 publication-title: Epidemiology (Cambridge, Mass.) doi: 10.1097/EDE.0b013e3181577654 contributor: fullname: von Elm – volume: 89 start-page: 145 issn: 0033-5622 issue: 2 year: 1996 ident: 26_34184545 publication-title: QJM doi: 10.1093/qjmed/89.2.145 – volume: 148 start-page: 30 issn: 0003-4819 issue: 1 year: 2008 ident: 33_29792151 publication-title: Annals of Internal Medicine doi: 10.7326/0003-4819-148-1-200801010-00190 |
SSID | ssj0009277 |
Score | 2.4051845 |
Snippet | Many physicians retain reservations regarding the routine prescription of renin-angiotensin blockade (RAB) in patients with atheromatous renovascular disease... BACKGROUNDMany physicians retain reservations regarding the routine prescription of renin-angiotensin blockade (RAB) in patients with atheromatous renovascular... |
SourceID | proquest crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 1403 |
SubjectTerms | Adult Aged Aged, 80 and over Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Angiotensin-Converting Enzyme Inhibitors - therapeutic use Atherosclerosis - drug therapy Atherosclerosis - mortality Biological and medical sciences Emergency and intensive care: renal failure. Dialysis management Female Follow-Up Studies Humans Intensive care medicine Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Prognosis Prospective Studies Renal Artery Obstruction - drug therapy Renal Artery Obstruction - mortality Renal failure Renin-Angiotensin System - drug effects Retrospective Studies Survival Rate |
Title | Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease |
URI | https://www.ncbi.nlm.nih.gov/pubmed/21993376 https://search.proquest.com/docview/963829888 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZbxMxELZCkRBShbgJR2UJXpdudr2xlzdUGipoy0si5W3l-GhairdKN5Xg1zNj7xURxPFiWZuspXi-jMeebz4T8mYsNN6CZCMtoYEdQxxJoVXEDQT7iYUg1esUnJyOj2bs0zybDwY3PdbSulq8VT-21pX8j1XhGdgVq2T_wbLtoPAA-mBfaMHC0P6VjT-cX2PypKl4wnPKhqexDmf0yKVzkXRn56WnqjtkqquvUnutEB_9ld_wWnTMHriOl9rP21w0Ak9g97a2BetNUMwE-5UXSL-UbjOtf7BcfQfbL8u1P40NgWhVX9cdVr76wDzQu7usUOuCPIe3Ix9_XsobLMMJNBDMYfUPLZD90XJdTHC0bBxHEC5kfU8cVAJqxLGeW0VRwd4SjSJdW91_kMZyGtavyZldsXyLyvbpl2IyOz4upofz6S1yO-F5hlTQj_OOGpQnnDdStnm6D-Pth9E2gpfdK7CJvLThApTf71B8pDK9T-7VWwz6PuDlARkY95DcOalJFI9I0cGGAgAowuad7wFoaGnpL6ChDWgo9PugoX3Q0Bo0j8lscjg9OIrqezYixUaiioQ1TIGv51ryVNmFUpZliRI8kRkEfFmW2lQvVDpSRnErpeWYHpZJnFsB_2mdPiE7rnTmGaECPmOxViOrJctw88FjvsiMsULqOGdD8rqZwOIqyKkUgQaRFjDNRZjmIdnbmNv2q3jlYgp7liGhzWQX4A4xxyWdgZ9d4HqS5EKIIXkajNC9jFxVWE-f__nlF-Ruh9qXZKdarc0rCD6rxZ5Hyk8H7JAh |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dispelling+the+myth%3A+the+use+of+renin-angiotensin+blockade+in+atheromatous+renovascular+disease&rft.jtitle=Nephrology%2C+dialysis%2C+transplantation&rft.au=Chrysochou%2C+Constantina&rft.au=Foley%2C+Robert+N&rft.au=Young%2C+James+F&rft.au=Khavandi%2C+Kaivan&rft.date=2012-04-01&rft.eissn=1460-2385&rft.volume=27&rft.issue=4&rft.spage=1403&rft.epage=1409&rft_id=info:doi/10.1093%2Fndt%2Fgfr496&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0931-0509&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0931-0509&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0931-0509&client=summon |